Beam Therapeutics Inc. Increase (Decrease) in Other Noncurrent Assets
Beam Therapeutics Inc. (BEAM) reported Increase (Decrease) in Other Noncurrent Assets of $197.00 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2024-02-27
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2021-09-30 was $0.00.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2021-06-30 was $12.00K.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for the quarter ending 2021-03-31 was $185.00K, a 140.26% increase year-over-year.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2021 was $197.00K, a 27.92% increase from fiscal 2020.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2020 was $154.00K, a 75.71% decline from fiscal 2019.
- Beam Therapeutics Inc. increase (decrease) in other noncurrent assets for fiscal 2019 was $634.00K.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-02-27 | $12.00K derived: sum of 3 quarters · filed 2024-02-27 | $197.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $12.00K derived: sum of 2 quarters · filed 2022-11-07 | $197.00K 10-Q · filed 2022-11-07 | $295.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $197.00K 10-Q · filed 2022-08-09 | $295.00K derived: sum of 3 quarters · filed 2023-02-28 | $283.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $185.00K 10-Q · filed 2022-05-09 | $283.00K derived: sum of 2 quarters · filed 2023-02-28 | $271.00K derived: sum of 3 quarters · filed 2023-02-28 | $262.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $98.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $86.00K derived: sum of 2 quarters · filed 2023-02-28 | $77.00K derived: sum of 3 quarters · filed 2023-02-28 | $154.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$21.00K derived: sum of 2 quarters · filed 2021-11-08 | $56.00K 10-Q · filed 2021-11-08 | $168.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $68.00K 10-Q · filed 2021-08-10 | $180.00K derived: sum of 3 quarters · filed 2022-02-28 | $624.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $77.00K 10-Q · filed 2021-05-11 | $189.00K derived: sum of 2 quarters · filed 2022-02-28 | $633.00K derived: sum of 3 quarters · filed 2022-02-28 | $633.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $556.00K derived: sum of 2 quarters · filed 2022-02-28 | $556.00K derived: sum of 3 quarters · filed 2022-02-28 | $634.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $444.00K derived: sum of 2 quarters · filed 2020-11-10 | $522.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $78.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $78.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |